The Crystec team have pioneered the development of mSAS®, a modified Supercritical Antisolvent process.
mSAS® is a powerful technology for engineering particles to improve the bioavailability, stability, and delivery of small molecule and large molecule therapeutics.
This unique platform enables the size and shape of particles to be finely tuned. Where required, more than one drug can be combined in a particle, or excipients incorporated in the particle to further enhance performance and reduce manufacturing complexity.
We design particles with the medicine in mind, hence Performance in Every Particle®.
In the mSAS® process drug molecule and any other required components are dissolved and introduced into a vessel together with a stream of supercritical carbon dioxide which rapidly extracts the solvent, enabling the drug to be precipitated under precise, tuneable conditions. Among the many strengths of the mSAS® platform are the ability to manipulate the crystallinity of small molecule therapeutics and to generate free-flowing powders of biomolecules whilst retaining high levels of activity.